🔎 Trials Near Me

Home › Treatment-Resistant Depressive Disorder › NCT06423430

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Recruiting

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS

Who can join

Ages 22 to 70 · All sexes

Full eligibility criteria
Inclusion Criteria:

1. The patient must be diagnosed with non-psychotic unipolar Major Depressive Disorder.
2. The patient must be in a major depressive episode for ≥12 months or have had at least 3 lifetime depressive episodes.
3. The patient has tried and failed a minimum of four different types of antidepressant treatments as measured by a tool designed for this purpose.
4. Depression medication and treatment regimen must be stable for a minimum of 4 weeks before the first baseline visit

Exclusion Criteria:

1. Pregnant or those who plan to become pregnant during study
2. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that could limit participation in the study or interfere with adherence to the study protocol.
3. Current or lifetime history of psychotic features in any Major Depressive Episode.
4. Has an intracranial Central Nervous System disease that impairs motor, sensory or cognitive function or that requires intermittent or chronic medication.
5. Significant acute suicide risk.
6. Diagnosis of Substance Use Disorder or Alcohol Use Disorder without sustained remission (12 months or longer).
7. Current and ongoing use of neurostimulation treatment that may interfere with DBS therapy/system.
8. Treatment with another investigational device or investigational drugs.

About the study

The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.

What is being tested

Sponsor: Abbott Medical Devices · Participants: 100 · Started: Sep 11, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06423430

Locations in the U.S.

AlabamaUniversity of Alabama at Birmingham - Dept. of Psychiatry, Birmingham
CaliforniaUCLA Department of Psychiatry, Los Angeles
USC University Hospital, Los Angeles (Not yet recruiting)
University of California at Davis, Sacramento
FloridaUSF Health, Tampa
GeorgiaEmory University Hospital, Atlanta
IllinoisRush University Medical Center, Chicago
IndianaIndiana University, Indianapolis
MassachusettsBeth Israel Deaconess Medical Center, Boston
Massachusetts General Hospital, Boston
MinnesotaUniversity of Minnesota Medical Center Fairview, Minneapolis (Not yet recruiting)
Mayo Clinic, Rochester
MissouriWashington University School of Medicine, St Louis
New JerseyRobert Wood Johnson University Hospital, New Brunswick
New YorkMount Sinai Hospital, New York
OhioThe Cleveland Clinic Foundation, Cleveland
The Ohio State University, Columbus
PennsylvaniaPennsylvania Hospital, Philadelphia
South CarolinaMedical University of South Carolina, Charleston
TexasUniversity of Texas Austin Dell Medical School, Austin
University of Texas Southwestern Medical Center at Dallas, Dallas
CHI St. Luke's Health Baylor College of Medicine Med. Ctr, Houston
The Methodist Hospital, Houston
UtahUniversity of Utah Hospital, Salt Lake City
WisconsinMedical College of Wisconsin, Milwaukee

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.